Informizely customer feedback surveys

[Skip to content]

Southern Health 70 years of the NHS; 1948 - 2018
Search our Site

EISAI E2609-G000-301 - A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease

The purpose of the study is to find out if an investigational study drug called elenbecestat (E2609) is effective for the treatment of Early Alzheimer’s disease (Mild Cognitive Impairment due to Alzheimer’s Disease or the early stages of Mild Alzheimer's Disease) when compared with a placebo. 

People with Alzheimer’s Disease or AD have an abnormal build-up of protein known as amyloid in their brain which is thought to lead to the memory loss and decline in other mental processes which worsen over time.  

Elenbecestat (E2609) is being developed to potentially reduce the amount of this protein build-up in the brain and thereby slow the progression of AD and the associated memory loss.


Who could be suitable? 

We are looking for volunteers aged between 50 and 85, with a diagnosis of Mild Cognitive Impairment or Mild Alzheimer’s Disease, who would score between 24-30 on the MMSE.

If you are interested in finding out more or if you would like to find out whether you would be suitable for this study please contact the MARC team on 02380 475206.